Jupiter Neurosciences, Inc.
JUNSHealthcare|Biotechnology|US
$2.20
+0.07 (+3.29%)
Cash / Share
$2.73
Financials
Financial Snapshot
Market Cap
$2.9M
Enterprise Value
$3.1M
Revenue (TTM)
$64.7K
Net Income (TTM)
-$9.2M
Cash & Investments
$1.5M
Net Cash
-$227.2K
Free Cash Flow (TTM)
-$7.2M
Operating CF (TTM)
-$7.2M
Debt/Equity
-4.78
Cash Runway & Burn Rate
Cash on Hand
$1.5M
Quarterly Burn
$1.8M
Monthly Burn
$604.1K
Est. Runway
~0.8 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.3K | $208.0K | $330.6K | $64.4K | $28.5K | $3.8M | $3.8M | $1.5M | |
| Operating Cash Flow | -$143.0K | -$254.8K | -$1.7M | -$1.2M | -$481.0K | -$3.9M | -$5.4M | -$7.2M | |
| Free Cash Flow | -$143.0K | -$254.8K | -$1.7M | -$1.2M | -$481.0K | -$3.9M | -$5.4M | -$7.2M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.00 | $4.00 | $3.00 | $4.00 | -$4.00 | $0.00 | |
| Financing Cash Flow | $107.8K | $461.5K | $1.9M | $982.3K | $445.0K | $7.7M | $5.4M | $6.9M |
R&D Spending
R&D (TTM)
-$214.8K
R&D Intensity
-332.0%
R&D Growth vs Prior
-110.3%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.1M | $638.0K | $233.3K | $0.00 | $0.00 | $21.8K | $64.7K | |
| R&D Expense | $685.7K | $1.6M | $1.4M | $942.8K | $954.8K | $492.7K | $2.1M | -$214.8K | |
| R&D % of Revenue | — | 145.7% | 226.9% | 404.2% | — | — | 9573.2% | -332.0% | |
| SG&A | $1.5M | $1.3M | $3.1M | $2.7M | $2.9M | $2.6M | $6.8M | $8.0M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.1M | $638.0K | $233.3K | $0.00 | $0.00 | $21.8K | $64.7K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.2K | $7.5K | |
| Gross Profit | $0.00 | $1.1M | $638.0K | $233.3K | $0.00 | $0.00 | $17.6K | $57.1K | |
| R&D | $685.7K | $1.6M | $1.4M | $942.8K | $954.8K | $492.7K | $2.1M | -$214.8K | |
| SG&A | $1.5M | $1.3M | $3.1M | $2.7M | $2.9M | $2.6M | $6.8M | $8.0M | |
| Operating Income | -$2.2M | -$1.9M | -$3.9M | -$3.4M | -$3.9M | -$3.1M | -$8.9M | -$9.8M | |
| Interest Expense | $317.1K | $13.5K | $114.0K | $740.9K | $218.7K | $248.4K | $66.0K | $206.9K | |
| Pretax Income | -$3.0M | -$1.7M | -$4.2M | -$5.0M | -$4.8M | -$2.4M | -$8.6M | -$9.2M | |
| Net Income | -$3.0M | -$1.7M | -$4.4M | -$5.0M | -$4.8M | -$2.4M | -$8.6M | -$9.2M | |
| EPS (Diluted) | -26.25 | -14.25 | -33.00 | -11.25 | -10.50 | -6.36 | -18.75 | -19.33 | |
| EBITDA | -$2.7M | -$1.6M | -$4.1M | -$4.2M | -$4.6M | -$2.2M | -$8.6M | -$9.3M | |
| Shares Out. (M) | 0.12 | 0.12 | 0.13 | 0.44 | 0.44 | 0.38 | 0.46 | 0.56 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.3K | $208.0K | $330.6K | $64.4K | $28.5K | $3.8M | $3.8M | $1.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.0K | $550.0K | $454.7K | $69.7K | $28.7K | $4.7M | $4.8M | $2.5M | |
| Total Assets | $6.2K | $550.0K | $667.4K | $235.9K | $148.6K | $6.2M | $5.6M | $3.7M | |
| Total Current Liabilities | $5.0M | $4.3M | $5.7M | $7.3M | $5.8M | $2.0M | $7.4M | $3.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $106.7K | $0.00 | $0.00 | $205.1K | |
| Total Liabilities | $5.0M | $4.3M | $5.8M | $7.4M | $5.9M | $2.0M | $7.4M | $4.1M | |
| Stockholders' Equity | -$5.0M | -$3.7M | -$5.2M | -$7.1M | -$5.8M | $4.2M | -$1.8M | -$366.0K | |
| Retained Earnings | -$8.0M | -$9.6M | -$13.8M | -$18.8M | -$23.6M | -$26.0M | -$34.7M | -$39.0M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$143.0K | -$254.8K | -$1.7M | -$1.2M | -$481.0K | -$3.9M | -$5.4M | -$7.2M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.00 | $4.00 | $3.00 | $4.00 | -$4.00 | $0.00 | |
| Free Cash Flow | -$143.0K | -$254.8K | -$1.7M | -$1.2M | -$481.0K | -$3.9M | -$5.4M | -$7.2M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $107.8K | $461.5K | $1.9M | $982.3K | $445.0K | $7.7M | $5.4M | $6.9M | |
| Issuance of Stock | $0.00 | $200.0K | $830.0K | $0.00 | $55.0K | $9.9M | $0.00 | $1.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$238.5K | $527.6K | $982.3K | $390.0K | -$2.2M | $5.4M | -$406.0K | |
| Stock Based Comp. | $944.6K | $563.5K | $1.3M | $817.3K | $1.2M | $1.8M | $2.4M | $108.0K | |
| Net Change in Cash | -$35.2K | $206.7K | $122.6K | -$266.2K | -$36.0K | $3.7M | $19.8K | -$356.4K |
Dilution Tracker
Shares outstanding grew 296.3% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+296.3%
Stock Issuance (TTM)
$1.9M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.12 | 0.12 | 0.13 | 0.44 | 0.44 | 0.38 | 0.46 | 0.56 | |
| Change vs Prior % | — | 0.0% | 8.6% | 246.6% | 0.0% | -12.5% | 20.3% | 20.8% | |
| Stock Issuance | $0.00 | $200.0K | $830.0K | $0.00 | $55.0K | $9.9M | $0.00 | $1.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $944.6K | $563.5K | $1.3M | $817.3K | $1.2M | $1.8M | $2.4M | $108.0K |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 100.0% | 100.0% | 100.0% | — | — | 80.6% | 88.3% | |
| Operating Margin % | — | -164.4% | -612.4% | -1471.4% | — | — | -40873.2% | -15166.7% | |
| Net Margin % | — | -146.9% | -686.4% | -2125.2% | — | — | -39662.8% | -14220.1% | |
| EBITDA Margin % | — | -145.7% | -640.4% | -1807.6% | — | — | -39359.9% | -14367.1% | |
| FCF Margin % | — | -22.6% | -271.9% | -535.2% | — | — | -24838.2% | -11206.0% | |
| ROE % | 60.7% | 44.6% | 84.6% | 69.4% | 82.5% | -58.5% | 471.9% | 747.3% | |
| ROA % | -49323.6% | -300.9% | -656.2% | -2101.2% | -3219.3% | -39.3% | -155.4% | -247.4% | |
| ROIC % | 57.2% | 51.4% | 86.3% | 65.4% | 108.9% | -70.4% | -255.4% | -709.4% | |
| R&D / Revenue % | — | 145.7% | 226.9% | 404.2% | — | — | 9573.2% | -332.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | -43.3% | -63.4% | -100.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -43.3% | -63.4% | -100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 14.9% | -111.0% | 12.1% | -12.8% | 20.1% | -188.2% | |
| Net Income | 0.0% | 45.7% | -164.7% | -13.2% | 3.5% | 49.0% | -254.4% | |
| EPS (Diluted) | 0.0% | 45.7% | -131.6% | 65.9% | 6.7% | 39.4% | -194.8% | |
| Operating Cash Flow | 0.0% | -78.2% | -581.0% | 28.0% | 61.5% | -713.2% | -38.4% | |
| Free Cash Flow | 0.0% | -78.2% | -581.0% | 28.0% | 61.5% | -713.2% | -38.4% | |
| R&D Expense | 0.0% | 139.4% | -11.8% | -34.9% | 1.3% | -48.4% | 323.5% | |
| SG&A Expense | 0.0% | -10.4% | 131.8% | -12.1% | 7.1% | -10.9% | 163.2% | |
| Total Assets | 0.0% | 8803.7% | 21.3% | -64.6% | -37.0% | 4074.1% | -10.3% | |
| Book Value / Share | 0.0% | 26.0% | -28.5% | 60.2% | 18.8% | 182.1% | -136.5% | |
| Debt | 0.0% | -91.0% | 500.3% | 191.5% | 18.5% | -90.3% | 2342.7% | |
| Diluted Shares | 0.0% | 0.0% | 8.6% | 246.6% | 0.0% | -12.5% | 20.3% |
Valuation
P/E (TTM)At Loss
P/S44.84
10Y Low / Med / High42.60 / 773.71 / 1620.54
P/B-3.35
EV/EBITDAAt Loss
EV/Revenue48.35
10Y Low / Med / High42.51 / 781.57 / 1690.73
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$2.73
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -15.69 | -28.89 | -12.48 | -36.60 | -39.21 | -126.18 | -4.08 | -0.11 | |
| P/S Ratio | 0.00 | 42.60 | 81.63 | 773.71 | 0.00 | 0.00 | 1620.54 | 44.84 | |
| P/B Ratio | -9.56 | -12.93 | -10.06 | -25.26 | -31.11 | 73.82 | -19.28 | -3.35 | |
| EV/EBITDA | -18.02 | -29.17 | -12.82 | -43.24 | -40.02 | -138.93 | -4.30 | -0.34 | |
| EV/Revenue | 0.00 | 42.51 | 82.13 | 781.57 | 0.00 | 0.00 | 1690.73 | 48.35 |
Analyst Estimates & Quality
Altman Z-Score
-23.09
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $12.1M | $7.4M |
| Net Income | $2.1M | -$9.0M |
| EPS | $4.50 | $-19.50 |
| # Analysts (EPS) | 1 | 1 |